

ORCA - Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:https://orca.cardiff.ac.uk/id/eprint/106628/

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Davies, William 2018. Sulfation pathways: The steroid sulfate axis and its relationship to maternal behaviour and mental health. Journal of Molecular Endocrinology 61, T199-T210. 10.1530/JME-17-0219

Publishers page: http://dx.doi.org/10.1530/JME-17-0219

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



The steroid sulfate axis and its relationship to maternal behavior

and mental health
William Davies ^{1,2,3} *
¹ School of Psychology, Cardiff University, Cardiff, UK
² Medical Research Council Centre for Neuropsychiatric Genetics and Genomics and
Division of Psychological Medicine and Clinical Neurosciences, School of Medicine,
Cardiff University, UK
³ Neuroscience and Mental Health Research Institute, Cardiff University, UK
*Correspondence address: School of Psychology, Tower Building, 70, Park Place,
Cardiff CF10 3AT, U.K. e-mail: daviesw4@cardiff.ac.uk Tel: +44-(0)29-2087-0152
Short title: Steroid sulfates and maternal mental health
Keywords: dehydroepiandrosterone sulfate, postpartum depression, postpartum
psychosis, steroid sulfatase, sulfotransferase
Main text word count: 5,257

Abstract

Steroid hormones can exist in functionally-dissociable sulfated and non-sulfated (free) forms and can exert profound effects on numerous aspects of mammalian physiology; the ratio of free to sulfated steroids is governed by the antagonistic actions of steroid sulfatase (STS) and sulfotransferase (SULT) enzymes. Here, I examine evidence from human and animal model studies which suggests that STS and its major substrate (dehydroepiandrosterone sulfate, DHEAS) and product (DHEA) can influence brain function, behavior and mental health, before summarising how the activity of this axis varies throughout mammalian pregnancy and the postpartum period. I then consider how the steroid sulfate axis might impact upon normal maternal behavior and how its dysfunction might contribute towards risk of postpartum psychiatric illness. Understanding the biological substrates underlying normal and abnormal maternal behavior will be important for maximising the wellbeing of new mothers and their offspring.

Word count: 140

An introduction to the steroid sulfate axis

Steroid hormones are synthesised within a number of endocrine body tissues (notably the adrenal gland, gonadal, breast, adipose and liver tissue in primates), and, as well as being utilised locally, may subsequently transported elsewhere to elicit widespread physiological effects. The hydrophobicity of free steroids limits their ability to be transported within aqueous media; hence, transport of these compounds is faciliated by the addition of negatively-charged sulfate groups through esterification by the steroid sulfotransferase (SULT) enzymes SULT1E1, SULT2A1, or SULT2B1b, or, to a lesser extent, by SULT1A1 or SULT2B1a (Salman *et al.* 2011, Mueller *et al.* 2015). In addition to increasing the solubility of steroids, sulfation processes also increase their stability: circulating concentrations of sulfated steroids are typically substantially higher than circulating concentrations of their free steroid counterparts, and the former may act as 'reservoirs' for the peripheral formation of bioactive hormones (Mueller *et al.* 2015). Many common steroids can be sulfated including cholesterol, pregnenolone, estrone and dehydroepiandrosterone (DHEA) (Mueller *et al.* 2015).

Upon influx into cells in target tissues via organic anion transporter proteins, sulfated steroids are typically desulfated by hydrolysis to their unconjugated forms, which are generally considered to be more biologically-active and which can act as precursors for a variety of androgens and estrogens. Whilst multiple sulfotransferases can facilitate sulfation according to tissue-type, there is just one ubiquitous enzyme which cleaves sulfate groups from steroids: steroid sulfatase (STS, formerly known as arylsulfatase C). In the interests of clarity and brevity, in this review I focus upon the physiological roles of STS and dehydroepiandrosterone (DHEA), whose sulfated form (DHEAS) is the most abundant circulating steroid in humans (Neunzig & Bernhardt 2014).

Steroid sulfatase: its regulation, expression and function

Steroid sulfatase is encoded by the X-linked *STS* gene (Xp22.3). As the human *STS* gene escapes X-inactivation (Shapiro *et al.* 1979), and as its Y-linked paralogue is pseudogenic (Yen *et al.* 1988), expression of STS is 1-2fold higher in female than male tissues (including brain) during development and into adulthood, although whether this expression difference translates to significantly greater enzyme activity in female tissues is debatable (Cuevas-Covarrubias *et al.* 1993, Miranda-Duarte *et al.* 1999, Ugele & Regemann 2000, Nakamura *et al.* 2003, Steckelbroek *et al.* 2004, Kriz *et al.* 2008, HE O'Brien *et al.* manuscript in preparation); nevertheless, the possibility certainly exists that the physiological consequences of STS activity modulation could feasibly be more profound in women than in men. STS is expressed in a number of tissues many of which are involved in reproductive function, including: the placenta (highest expression), brain, ovary, mammary gland, testis, adipose tissue, thyroid gland and skin (Salido *et al.* 1990, Miki *et al.* 2002, Steckelbroek *et al.* 2004, Stergiakouli *et al.* 2011, https://www.ncbi.nlm.nih.gov/unigene accessed 12th September 2017).

At the cellular level, the STS protein is largely located in the endoplasmic reticulum of the cell where it functions as a glycosylated homodimer; the catalytic activity of STS is dependent upon the presence of sulfatase-modifying factors (SUMFs) (Mueller *et al.* 2015). STS activity appears to be increased in response to stress/inflammation in various tissues with the gene being a target of NF-κB; the resultant free steroid products, notably estrogens, may act as inflammation-suppressors (Dias & Selcer 2016, Jiang *et al.* 2016). STS has long been recognised as a therapeutic target in hormone-dependent cancers, and a number of effective and specific STS inhibitors have been developed which reduce the pool of androgens and estrogens in the vicinity of the cancer and which have potential clinical benefits (Purohit & Foster 2012).

The steroid sulfatase axis: its influence on brain function and behavior

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

Seminal work in rodents suggested that, in mammals, some steroids (and hence their sulfate conjugates) such as DHEA(S) could be synthesised de novo in the brain and may be regarded as neurosteroids (Corpechot et al. 1981). Subsequent work has shown that, whilst DHEA biosynthesis within the brain is possible, a second route by which DHEA appears in the brain in rodents (and feasibly humans too) is through the uptake, and subsequent rapid desulfation, of circulating DHEAS by organic ion transporters and steroid sulfatase respectively in the capillaries of the blood-brain barrier (Qaiser et al. 2017). Whilst the expression patterns of STS in the human blood-brain barrier have yet to be systematically assessed, in the developing human brain, STS is highly expressed throughout the thalamus with lower expression also seen in the olfactory epithelium, the cerebral cortex, the basal ganglia, the hypothalamus and pituitary gland, the choroid plexus and the cerebellar neuroepithelium (Stergiakouli et al. 2011); in adulthood, high levels of STS expression and associated enzyme activity persist in these regions (Perumal et al. 1973, Steckelbroeck et al. 2004, Kriz et al. 2008). Although STS activity in the brain is likely to have important and widespread developmental and ongoing effects (see later), sulfatase activity in this tissue is apparently dominated by sulfotransferase activity, and, in support of this idea, levels of sulfated steroids in the human brain (including those of DHEAS) may be relatively high (Maninger et al. 2009, Mueller et al. 2015).

At the molecular level, free and sulfated steroid hormones can modulate receptors influencing acute neuronal inhibition and excitation, as well as neurodevelopmental processes. For example, both DHEAS and pregnenolone sulfate act as antagonists at GABAA receptors, as agonists at σ receptors, and as positive modulators at N-methyl-D-aspartic acid (NMDA) receptors (Reed *et al.* 2005, Qaiser *et al.* 2017). Importantly, the sulfated and unconjugated steroids may have differential effects and potencies e.g. DHEA has been

reported to act as a weaker GABA_A antagonist than DHEAS (Reed *et al.* 2005, Maninger *et al.* 2009). In addition to relatively weak agonistic effects at the androgen and estrogen receptors, DHEA and DHEAS may bind to, and activate, neurotrophin TrkA and p75^{NTR} receptors to attenuate neuronal apoptosis and hence influence neurodevelopment (Lazaridis *et al.* 2011).

Insights into the behavioral and brain processes that are mediated by STS and DHEA(S), potentially via the aforementioned molecular mechanisms, can be obtained by examining phenotypes in individuals in which: a) the STS gene is rendered non-functional (by natural or experimental means), b) the STS enzyme is acutely inhibited by a selective drug, or c) DHEA(S) has been administered. Less convincingly, it is possible to investigate the extent to which (peripheral) levels of DHEA(S) correlate with brain/ behavioral phenotypes of interest, and hence the extent to which changes in the former may cause the latter.

In humans, *STS* deficiency (arising from partial or complete deletion of the gene, or inactivating point mutations within it) results in the rare dermatological condition X-linked ichthyosis (XLI) (Fernandes *et al.* 2010). XLI chiefly affects males, and is associated with an elevated DHEAS/DHEA serum ratio, especially pre-pubertally (Idkowiack *et al.* 2016). Whilst there is currently little published literature on brain structure/function and biochemistry in individuals with XLI (Trent & Davies 2013), there is an emerging literature suggesting that boys with the condition may be at increased risk of developmental disorders such as Autism Spectrum Conditions (ASCs), Attention Deficit Hyperactivity Disorder (ADHD), and early-onset psychotic disorders (Kent *et al.* 2008, Chatterjee *et al.* 2016, Malik *et al.* 2017) whilst men with the condition may be at increased risk of both developmental and mood (unipolar depression and bipolar) disorders (Chatterjee *et al.* 2016). There is also some evidence that genetic variation within *STS* is associated with measures of attention in both clinical (ADHD) (Brookes *et al.* 2010, Stergiakouli *et al.* 2011, Wang *et al.* 2017) and healthy (Humby *et al.* 2017)

populations. These behavioral findings are consistent with the high expression of STS in brain regions involved in integrating and acting upon sensory information, and executive function.

Recapitulating the clinical findings in XLI, mice in which the *Sts* gene is deleted (or in which the STS enzyme is inhibited) show significantly reduced levels of serum DHEA and associated impairments in attention, altered response inhibition, hyperactivity, heightened emotional reactivity and aggression, and increased levels of behavioral perseveration (Davies *et al.* 2009, Trent *et al.* 2012b, Trent *et al.* 2013, Davies *et al.* 2014). Animal models allow the neurochemistry underlying behavioral abnormalities to be studied. *Sts* deletion in mice is associated with higher serotonin levels in the striatum and hippocampus (together with elevated hippocampal expression of the serotonin receptor 2c (*Htr2c*) gene), and reduced striatal noradrenaline turnover; the extent of serotonergic perturbation in *Sts*-deficient mice seems to correlate with the severity of some behavioral phenotypes (Trent *et al.* 2012a). Pharmacological studies in rats in which the STS enzyme was acutely inhibited have revealed changes in hippocampal acetylcholinergic release together with parallel changes in memory function (Rhodes *et al.* 1997, Babalola *et al.* 2012, Yue *et al.* 2016).

Experimental and correlational studies in animal models and human populations have linked altered DHEA(S) levels to a diverse and important range of behavioral phenotypes including: sexual function (Peixoto *et al.* 2017), aggression (Nicolas *et al.* 2001, Soma *et al.* 2015), locomotor activity (Strous *et al.* 2001, Trent *et al.* 2012b, Trent *et al.* 2013) and numerous aspects of mood and cognition (including attention) (Rhodes *et al.* 1996, Davies *et al.* 2009, Pluchino *et al.* 2015, Starka *et al.* 2015).

The data presented above establish that steroid sulfatase (and its dysfunction) can impact extensively upon normal brain function via multiple neural and neurochemical pathways; this action may be direct (i.e. within the brain itself), or, alternatively, may result

from extra-brain STS activity impacting upon the production and action of circulating levels of sulfated and free steroids including DHEA(S).

Changes in the steroid sulfate axis throughout mammalian pregnancy and the postpartum

period

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

Throughout the childbearing process, women experience considerable hormonal fluctuations, including with regard to the steroid sulfate axis (Tal et al. 2000). However, longitudinal studies in which the levels, and sulfation status, of multiple hormones are measured across pregnancy and the postpartum period are scarce. Due to ethical and practical issues, most information in humans comes from analysis of peripheral tissues (blood, serum/ plasma, saliva and rarely cerebrospinal fluid) and therefore its relevance to the hormonal milieu experienced directly by the brain is questionable. Moreover, peripherallydetected maternal hormone levels may be influenced by multiple variable factors including: breastfeeding, stress exposure, use of recreational and therapeutic drugs, parity, maternal age and diet, and gender/number/size of the fetus(es), and understanding how unstable hormone levels relate to specific physiological phenotypes is therefore challenging. Whilst the use of neurobiologically-amenable mammalian animal models in which experimental variables can be controlled may circumvent these issues to some extent in in vivo systems, such models differ from humans in terms of both circulating hormone levels and reproductive traits such as number of offspring per pregnancy, or the extent and duration of postnatal maternal care; hence, extrapolating from models to man (or woman) should be done with caution.

In humans, from around nine weeks of pregnancy, a key role of the steroid sulfate axis is to generate precursors for the production of estrogens to be secreted into the maternal and fetal bloodstreams. Initially, sulfated C-19 steroids including DHEAS and 16α -OH-DHEAS

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

produced by the maternal and fetal adrenal glands and fetal liver must undergo hydrolyis in the STS-rich syncytiotrophoblast of the placenta (Salido *et al.* 1990) before conversion by a series of enzymatic reactions to estrogens including estrone, estriol and estradiol; estrone, but not estradiol, is subsequently sulfated in the mother (Geyer *et al.* 2017).

As healthy pregnancies progress, there is a consistently-observed decrease in maternal DHEAS serum levels from non-pregnancy levels (apparently independent of fetal gender), perhaps as DHEAS is increasingly utilised for estrogen synthesis in the developing placenta; after parturition, maternal serum DHEAS levels rapidly rebound to pre-pregnancy levels (Tagawa et al. 2004, Soldin et al. 2005, Kuijper et al. 2013, Farrar et al. 2014). The data regarding systemic maternal DHEA levels throughout pregnancy and the postpartum period are less consistent. Some studies have demonstrated elevated serum/plasma DHEA levels during early-mid pregnancy, with a subsequent gradual decline up to one year postpartum (Nieschlag et al. 1974, Buckwalter et al. 1999, Tagawa et al. 2004); given DHEA's immunosuppressive effects and an increase in maternal cytokine markers after childbirth, this pattern of effects has been postulated to provide maximum protection for the incipient fetus from maternal immune surveillance (Tagawa et al. 2004). Other studies have suggested that peripheral DHEA levels are relatively unaffected by pregnancy and parturition (Buster et al. 1979, Soldin et al. 2005) or even that they increase across pregnancy and towards parturition in peripheral tissues (saliva or plasma) (Bird et al. 1980, Hampson et al. 2013). If DHEAS levels do fluctuate as outlined above during pregnancy/postpartum period, and DHEA levels remain in a comparatively steady state, then the DHEA/DHEAS ratio would be expected to be high during pregnancy and low during the postpartum period relative to values in non-pregnancy; in healthy populations where this ratio has been assessed longitudinally, this pattern of effects is indeed observed (Hill et al. 2002, Tagawa et al. 2004).

Presumably the above changes in DHEA/DHEAS ratio over the course of pregnancy and the postpartum period are related to the relative abundance and/or activity of the steroid sulfatase and sulfotransferase enzymes in cells contributing towards the hormonal milieu of the periphery. A main contributor to this ratio is the syncytiotrophoblast cells of the placenta, and expulsion of the STS-rich placenta after birth likely explains the rapid restoration of circulating maternal DHEAS levels. However, other tissues may also contribute: in healthy women, STS activity in leukocytes has been reported to be greater in third trimester pregnant women than in first trimester pregnant, or non-pregnant, women (Miyakawa *et al.* 1994), a finding consistent with the observed high DHEA/DHEAS ratio during late pregnancy. To the best of my knowledge, there has not yet been any systematic analysis of peripheral (leukocyte) STS activity throughout the postpartum period in humans.

Peripheral levels of sulfated and free steroids cannot provide reliable information on the activity of steroid sulfatase in the brain, and direct measurement of brain STS activity throughout pregnancy and the postpartum period in humans is currently unachievable. However, animal models, such as rodents, might provide some insights into human physiology (bearing in mind the caveats discussed above with respect to cross-species extrapolation). Mortaud and colleagues (1996) showed that, in whole female mouse brain, STS protein levels were more than two-fold higher in the lactating (postpartum) state relative to the pregnant (stage not specified) or non-pregnant state; whether this increase in protein level corresponded to an increase in enzyme activity in this state, or with brain DHEA(S) levels, was not assessed. Conversely, in rats, neither STS brain activity nor sulfotransferase liver activity appear to be affected by pregnancy or parturition although only cortical (as opposed to whole) brain tissue was analysed (Maayan *et al.* 2004a). Interestingly, data on STS activity in rat leukocytes partially resemble those seen in humans, in that activity is significantly higher

in late-pregnancy animals (18 days post conception) than in non-pregnant animals, and activity becoming even more pronounced 24hrs after giving birth (Maayan *et al.* 2004a). In rat serum and brain cortex, the DHEA/DHEAS ratio is significantly, and equivalently, elevated in late pregnancy and early postpartum animals compared to non-pregnant control females (Maayan *et al.* 2004a).

In summary, the sparse human and rodent data presented above are reconcilable with the proposal that in non-cortical regions of the mammalian brain, and in certain cells of the immune system, STS levels/activity increase over the course of pregnancy before peaking during late pregnancy and into the early postpartum period.

A possible role for the steroid sulfate axis in normal maternal behavior

Androgen-related metabolic pathways, including the STS/DHEA(S) axis, are known to modulate physiological processes asociated with parturition (Makieva *et al.* 2014). Given the previously-described role of the steroid sulfatase axis in brain and behavioral function, its increased activity in the perinatal period may be related to, and potentially be causal for, the emergence of maternal behaviors designed to nourish and protect their offspring. These behaviors, many of which are highly-conserved across mammalian species, include: nest-building, huddling, nursing and social interaction with the offspring mediated by olfactory, visual, auditory and somatosensory cues, altered (generally decreased) levels of anxiety with increased exploratory behavior, and aggression directed towards threatening predators/society members but not offspring (Bridges 2015, Lonstein *et al.* 2015). In rodents, and probably also in humans, the quality and intensity of expressed maternal behaviors is related to maternal cognitive (executive) function, particularly in the domains of offspring-related learning and memory processes, attention to relevant care cues, behavioral flexibility and impulse regulation; interestingly, in rats, reduced maternal behavior is associated with

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

impaired performance on attentional set-shifting and startle/prepulse inhibition tasks, whilst increased maternal care (pup-licking) is related to reduced motor impulsivity (Lonstein et al. 2015). In non-primate species, and in primates to a lesser extent, these behaviors are driven by hormonal mechanisms acting via a multitude of brain regions and neurochemical systems, including the prefrontal cortex, the amygdala, the cholinergic basal forebrain activating system and the GABAergic and serotonergic systems (Bridges 2015, Lonstein et al. 2015). The fact that manipulation of the STS axis in males affects many of the cognitive/behavioral phenotypes and neurobiological systems listed above (notably attention, social interaction, emotional reactivity, aggression, memory, behavioral flexibility and motor impulsivity (Mortaud et al. 1996, Rhodes et al. 1997, Kent et al. 2008, Davies et al. 2009, Trent et al., 2012a,2012b, Trent et al. 2013, Davies et al. 2014, Chatterjee et al. 2016)) supports the argument that the STS axis influences neural processes pertinent to maternal care efficacy in females. To explicitly test the idea that the STS axis influences maternal perinatal behavior, studies will need to be undertaken in non-pregnant (control), pregnant and postpartum female animal models and human subjects in which STS activity is compromised, or in which DHEA(S) levels are systematically varied and assayed.

To date, the only available *Sts*-deficient genetic rodent models have been chromosomally-mutant mice that are necessarily male (Trent *et al.* 2012b), but new gene editing technology should hopefully allow the generation of *Sts*-deficient female rodents (Baud & Flint 2017). The expectation that such genetically-modified female rodents may exhibit STS-dependent abnormal maternal behaviors has been raised by a recent pharmacological study in our laboratory. Briefly, we showed that acute inhibition of STS in new mouse mothers resulted in anxiety-related phenotypes (a reduced startle response, and increased rearing and exploratory drive on the elevated plus maze), but no gross

abnormalities in nest maintenance or in mother-pup interactions (Humby *et al.* 2016). At this stage, we cannot discount the fact that there were subtle, undetectable, irregularities in dampup interactions, especially in light of the fact that inhibitor-treated mothers exhibit substantial dysregulation of olfactory-related gene expression in the brain (W Davies, unpublished results). Furthermore, as we did not examine the behavioral effects of acute STS inhibition in female mice with other physiological statuses (virgin, non-virgin but non-pregnant, and pregnant), we cannot definitively say that the behavioral effects mediated by the STS axis are specific to the postpartum period; this extended analysis is ongoing. We are currently undertaking a parallel systematic study of behavior, including perinatal behavior, in STS-deficient women with a view to determining which, if any, psychological processes are affected by their genetic mutation.

Additional evidence that DHEA(S) participate in normal perinatal maternal behaviors in humans may be obtained by showing behavioral effects elicited by administration to new mothers, or through identifying significant correlations between systemic DHEA(S) levels and behavioral/cognitive measures in healthy (or general population) postpartum mothers. Although DHEAS administration has been performed in postpartum women (e.g. Aisaka *et al.* 1984) there is no reliable published data available regarding parallel behavioral changes. In healthy women selected from the general population, there is some evidence for an association between higher serum DHEA levels, enhanced mood and aspects of better cognitive performance during late pregnancy (~20 days prior to delivery) and the postpartum period (~26 days after delivery) (Buckwalter *et al.* 1999), although no similar relationship seems to exist for DHEAS levels (Farrar *et al.* 2014).

Postpartum psychiatric disorders

A significant proportion of women experience mental health issues manifesting in late pregnancy and/or in the postpartum period. These can range from relatively common and comparatively mild conditions which do not require medical intervention (so-called 'baby blues') to rarer, more severe, persistent and disabling disorders which require urgent medical care; the latter category of disorders includes postpartum depression, obsessive-compulsive disorder and anxiety disorders (Sharma & Sommerdyk 2015, Stewart & Vigod 2016, Pawluski et al. 2017). If the steroid sulfate axis is indeed a major player in maternal brain and behavioral function in late pregnancy and the postpartum period as has been argued above, then, logically, its dysfunction might reasonably be considered a risk factor for vulnerability to maternal mental health conditions in this period. In the following section, I discuss the nature and aetiology of one extremely severe and poorly-understood psychiatric disorder associated with childbirth, postpartum (or puerperal) psychosis, and consider evidence implicating steroid sulfate axis abnormalities in its pathogenesis.

The nature and etiology of postpartum psychosis

Postpartum psychosis (PP) is estimated to affect 1-2 in every 1000 new mothers (VanderKruik et al. 2017). Symptoms associated with the condition include hallucinations, delusions (often related to the newborn child), cognitive disorganisation, anxiety, and mood abnormalities, and these tend to present within the first two weeks (and frequently within the first few days) of childbirth; PP symptoms can impact massively upon normal mother-child bonding and family life, and affected mothers are at elevated risk of committing suicide or infanticide (Bergink et al. 2016). Whilst there is thought to be a considerable biological component to disorder vulnerability, the exact nature and contribution of underlying biological risk factors is currently obscure (Jones et al. 2014, Bergink et al. 2016). Understanding these may help to

develop better predictive biomarkers for the condition, as well as more effective and safer treatment options (Davies 2017). Epidemiological data has suggested considerable overlap with bipolar disorder, autoimmune thyroid conditions, and pre-eclampsia (Jones *et al.* 2014, Bergink *et al.* 2016); other studies have implicated an abnormal (over-active) immune system (Bergink *et al.* 2013, Kumar *et al.* 2017), autoimmune anti-NMDA receptor encephalitis (Bergink *et al.* 2015), and serotonergic system dysfunction (Kumar *et al.* 2007, Davies 2017) in risk. A genetic linkage study in bipolar postpartum psychosis implicated significant and suggestive loci at 16p13 and 8q24 respectively (Jones *et al.* 2007), but, to date, findings from small-scale (and therefore underpowered) candidate gene and genome-wide association studies have been unconvincing or non-significant, and none have yet implicated X-linked genetic risk variants.

Steroid sulfate axis dysfunction and postpartum psychosis risk

There are several lines of basic and clinical evidence suggesting that abnormalities with the steroid sulfate axis (and most likely steroid sulfatase deficiency (Davies 2012)) may influence PP risk: a) the axis appears to exert disproportionately large effects in the late pregnancy/early postpartum period, so any disruption to it may impact relatively specifically on this timepoint, b) estrogens are generally thought to be protective against psychosis (Reicher-Rossler 2017) and STS deficiency, in women, as in men (Lykkesfeldt *et al.* 1985), is expected to result in lower levels of circulating estrogens as a consequence of reduced levels of DHEA precursor, c) genetic deletions encompassing *STS* have been associated with psychotic disorders (paranoid and early-onset schizophrenia) in case studies (Milunsky *et al.* 1999, Malik *et al.* 2017), d) STS brain expression is high in regions previously implicated in psychotic disorders (Fusar-Poli *et al.* 2011, Dietsche *et al.* 2017), e) the neurochemical abnormalities associated with psychosis and remediable by antipsychotic treatment overlap

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

considerably with those influenced by STS and DHEA(S) i.e. of the serotonergic system (notably the 5-HT_{2C} receptor)(Meltzer et al. 2012, Selvaraj et al. 2014), the hippocampal cholinergic system (Olincy & Freedman 2012, Carruthers et al. 2015), the GABAA system (Egerton et al. 2017), and of NMDA receptor signalling (notably in the thalamus)(Vukadinovic 2014, Harrison 2015), f) STS-deficient humans and mice exhibit a range of PP-relevant phenotypes including inattention and emotional instability, whilst genetic variants within STS in man are associated with cognitive disorganisation (see above), g) STS is highly-expressed in the hypothalamus, pituitary gland and the thyroid gland (Stergiakouli et al. 2011) and its absence in these tissues could potentially explain high rates of hypothalamus-pituitarythyroid axis dysfunction and autoimmune thyroid dysfunction in PP, h) abnormal placental and whole blood STS expression is associated with pre-eclampsia (Gratton et al. 2016), i) levels of salivary DHEAS during late pregnancy and in the early postpartum period (10 days after birth) positively correlate with measures of anxiety, phobia, paranoia and psychoticism in previously-healthy women, with highest DHEAS levels (consistent with impaired or absent STS activity) being associated with significant psychiatric distress (Marrs et al. 2009, Marrs et al. 2010), j) lithium, an established effective treatment for mania in bipolar disorder and PP, enhances the serum DHEA/DHEAS ratio in rats consistent with a stimulatory effect on STS, whilst reducing both brain and serum levels of DHEAS (Maayan et al. 2004b), k) pathologicallyreduced levels of immunosuppressive DHEA in the postpartum period as a consequence of STS deficiency may feasibly contribute towards the immune hyper-activation seen in PP and I) STS and the HTR2C (5-HT_{2C}) gene lie under candidate quantitative trait loci linkage peaks in a porcine model of PP (Quilter et al. 2007). Finally, the prevalence of STS deficiency i.e. heterozygosity or homozygosity for null mutations in women is estimated to be ~1 in 950 individuals (based upon the general population frequency of STS deficiency in males (Langlois

et al. 2009, Craig et al. 2010) and de novo versus inherited mutation rates (Cuevas-Covarrubias et al. 1999)); this rate is consistent with it being a risk factor for PP, although clearly, as for most mood and psychotic disorders, multiple interacting genetic and environmental risk factors are likely to influence overall PP vulnerability.

Future analyses, in STS-deficient women or in *Sts*-deficient female rodents, are likely to provide evidence for or against the hypothesis that this molecular perturbation increases PP risk, although such studies will likely be limited by available sample size, by the infrequency of the condition, and by cross-species extrapolation issues. Further studies in healthy women in late pregnancy and the postpartum period, which will be less constrained by sample size, might examine if, and how, peripheral steroid sulfatase activity (in addition to DHEA(S) levels) correlate with dimensional behavioral measures related to PP (e.g. psychoticism). Alternative complementary work in clinical PP populations might investigate: a) variability within the *STS* gene (where rates of causal polymorphisms/mutations might be expected to differ from control women), b) STS activity in accessible tissues such as leukocytes (lower activity anticipated in women affected by PP than in controls) or c) peripheral baseline and stressevoked levels of DHEA(S)(higher DHEAS/DHEA ratios expected in affected women versus control subjects).

Our mouse studies have provided preliminary evidence somewhat supportive of the notion of STS deficiency as a risk factor for PP. Briefly, we found that the behavioral phenotypes elicited by STS inhibition in new mothers could be partially reversed by administration of the clinically-efficacious antipsychotic drug ziprasidone, thus indicating their potential relevance to PP (Humby *et al.* 2016). Additionally, and intriguingly, STS-inhibited mice demonstrated abnormal gene expression within a small region of chromosome 15 (equivalent to the 8q24 candiate genomic region implicated by linkage in PP), which could

also be normalised by ziprasidone administration, providing further support for the model's face and predictive validity and thus its utility for understanding the mechanistic basis of PP risk (Humby *et al.* 2016).

Steroid sulfate axis dysfunction in other postpartum psychiatric disorders

Postpartum psychosis is an umbrella term covering a wide variety of behavioral and psychiatric symptoms, in addition to psychosis, that present shortly after childbirth. Many of these symptoms (which can include depressive and manic episodes, anxiety and obsessivecompulsive tendencies) may also be seen, to varying extents, in cases of other differentiallydefined postpartum psychiatric conditions such as postpartum depression, and could be underpinned by common biological processes. Much of the logic implicating steroid sulfate axis dysfunction in general, and STS deficiency in particular, in PP pathophysiology may be equally applied to these alternative disorders, especially considering that their occurrence may, in part, be due to abnormalities in physiological and neurochemical systems affected by this axis i.e. steroid hormone levels, the hypothalamic-pituitary-adrenal axis, the thyroid system, markers of inflammation and the GABAergic, noradrenergic and serotonergic systems (Speisman et al. 2011, Skalkidou et al. 2012, Pawluski et al. 2017). The observed effects of STS deficiency on mood modulation (Chatterjee et al. 2016), behavioral (in)flexibility (Trent et al. 2013) and anxiety-related processes (Trent et al. 2012b, Chatterjee et al. 2016) implicate it as a candidate risk factor in postpartum depression, OCD, and anxiety respectively. The steroid sulfate axis could also feasibly mediate the effects of environmental factors (e.g. stressors such as childhood maltreatment) on mothers' vulnerability to a range of postpartum psychiatric illnesses, and potentially even on their infants health (Sexton et al. 2015, Schury et al. 2017).

435

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

Evidence examining rates of these various postpartum psychiatric conditions and associated behavioral and physiological markers remains to be collected in STS-deficient individuals and animal models; conversely, rates of STS deficiency remain to be determined in patients ascertained on the basis of having been diagnosed with such postpartum conditions. However, there is some limited existing data, consistent with the STS deficiency risk hypothesis, suggesting that circulating maternal DHEA plasma levels may be abnormally low prior to, and during the onset of, postpartum depression (Gelman *et al.* 2015), and that DHEA supplementation can benefit mood in depressed individuals (although consistent therapeutic benefits of this intervention in the postpartum period have yet to demonstrated)(Soares & Phillips 2006, Peixoto *et al.* 2014).

Conclusions and future work

Above I have discussed the mounting evidence (admittedly mainly obtained in male test subjects to date) that steroid sulfatase, and the reactions it catalyses, have important roles in a wide variety of important brain and behavioral functions. As the activity of the STS axis fluctuates across numerous tissues (including brain) during pregnancy, and into the postpartum period, it is conceivable that this axis bears upon normal maternal behavioral phenotypes and its influence in this respect remains to be tested using genetic and pharmacological approaches in clinical and model populations. In particular, gene expression changes elicited by manipulations of the steroid sulfate axis may be compared against those seen in the healthy postpartum maternal brain (Gammie *et al.* 2016). It also follows that, potentially, STS axis dysfunction may be associated with postpartum psychiatric conditions, and there is some circumstantial evidence, notably in postpartum psychosis, that this may be the case. Genetic and endocrine analyses in women previously affected by, or at high of

developing, postpartum psychiatric conditions should be able to experimentally test this hypothesis.

Of course, whilst I have focussed upon the possible impact of STS and DHEA(S) on maternal behavior here, it is naïve to think that these molecules act in isolation to affect this phenotype. As such, future studies should aim to supplement the currently available, very limited, data relating to the brain and peripheral expression and activity of enzymes and compounds involved in DHEA(S) biosynthesis and metabolism (notably the SULTs and SUMFs) across pregnancy and the postpartum period in healthy women, women affected by postpartum psychiatric illness, and relevant mammalian animal models, with a view to understanding how these components interact to generate healthy or abnormal behaviours. Work in model systems in particular may highlight molecules and pathways which mediate the behavioral effects of the steroid sulfate axis, and which could theoretically comprise novel therapeutic targets. For example, our nascent mouse work has implicated the CCN family of proteins as potentially-druggable targets in cases of PP (Davies, 2017). Pharmacological or genetic targeting of such mediators might result in lower levels of side-effects compared to the systemic administration of compounds such as DHEA or estrogens which have androgenic/estrogenic potential and which elicit widespread effects on multiple physiological systems (Gentile 2005, Rutkowski et al. 2014).

485	Declaration of interest
486	There is no conflict of interest that could be perceived as prejudicing the impartiality of this
487	review.
488	Funding
489	This work was undertaken within the Medical Research Council UK Centre for
490	Neuropsychiatric Genetics and Genomics (MR/L010305/1) but did not receive any specific
491	grant from any funding agency in the public, commercial or not-for-profit sector.
492	
493	
494	
495	
496	
497	
498	
499	
500	
501	
502	
503	
504	
505	
506 507	
508	
509	
510	
511	
512	

References

- Aisaka K, Mori H, Ogawa T & Kigawa T 1984 Effects of dehydroepiandrosterone-sulphate
- 515 (DHEA-S) administration on puerperal lactation and maternal prolactin and estradiol levels.
- 516 Nihon Sanka Fujinka Gakkai Zasshi **36** 1935-1942.
- Babalola PA, Fitz NF, Gibbs RB, Flaherty PT, Li PK & Johnson DA 2012 The effect of the steroid
- sulfatase inhibitor (p-O-sulfamoyl)-tetradecanoyl tyramine (DU-14) on learning and memory
- 519 in rats with selective lesion of septal-hippocampal cholinergic tract. Neurobiol Learn Mem 98
- 520 303-310.
- 521 Baud A & Flint J 2017 Identifying genes for neurobehavioral traits in rodents: progress and
- 522 pitfalls. *Dis Model Mech* **10** 373-383.
- 523 Bergink V, Armangue T, Titulaer MJ, Markx S, Dalmau J & Kushner SA 2015 Autoimmune
- 524 Encephalitis in Postpartum Psychosis. *Am J Psychiatry* **172** 901-908.
- Bergink V, Burgerhout KM, Weigelt K, Pop VJ, de Wit H, Drexhage RC, Kushner SA & Drexhage
- 526 HA 2013 Immune system dysregulation in first-onset postpartum psychosis. *Biol Psychiatry* **73**
- 527 1000-1007.
- 528 Bergink V, Rasgon N & Wisner KL 2016 Postpartum Psychosis: Madness, Mania, and
- 529 Melancholia in Motherhood. *Am J Psychiatry* **173** 1179-1188.
- Bird CE, Cook SJ, Dressel DE & Clark AF 1980 Plasma C19-delta 5-steroid levels during normal
- 531 human pregnancy. *Clin Biochem* **13** 126-128.
- 532 Bridges RS 2015 Neuroendocrine regulation of maternal behavior. Front Neuroendocrinol 36
- 533 178-196.
- Brookes KJ, Hawi Z, Park J, Scott S, Gill M & Kent L 2010 Polymorphisms of the steroid sulfatase
- 535 (STS) gene are associated with attention deficit hyperactivity disorder and influence brain
- tissue mRNA expression. *Am J Med Genet B Neuropsychiatr Genet* **153B** 1417-1424.

Buckwalter JG, Stanczyk FZ, McCleary CA, Bluestein BW, Buckwalter DK, Rankin KP, Chang L & 537 Goodwin TM 1999 Pregnancy, the postpartum, and steroid hormones: effects on cognition 538 539 and mood. Psychoneuroendocrinology 24 69-84. 540 Buster JE, Chang RJ, Preston DL, Elashoff RM, Cousins LM, Abraham GE, Hobel CJ & Marshall JR 1979 Interrelationships of circulating maternal steroid concentrations in third trimester 541 pregnancies. II. C18 and C19 steroids: estradiol, estriol, dehydroepiandrosterone, 542 dehydroepiandrosterone sulfate, delta 5-androstenediol, delta 4-androstenedione, 543 544 testosterone, and dihydrotestosterone. J Clin Endocrinol Metab 48 139-142. Carruthers SP, Gurvich CT & Rossell SL 2015 The muscarinic system, cognition and 545 546 schizophrenia. Neurosci Biobehav Rev 55 393-402. Chatterjee S, Humby T & Davies W 2016 Behavioral and Psychiatric Phenotypes in Men and 547 Boys with X-Linked Ichthyosis: Evidence from a Worldwide Online Survey. PLoS One 11 548 549 e0164417. 550 Corpechot C, Robel P, Axelson M, Sjovall J & Baulieu EE 1981 Characterization and measurement of dehydroepiandrosterone sulfate in rat brain. Proc Natl Acad Sci U S A 78 551 4704-4707. 552 Craig WY, Roberson M, Palomaki GE, Shackleton CH, Marcos J & Haddow JE 2010 Prevalence 553 of steroid sulfatase deficiency in California according to race and ethnicity. Prenat Diagn 30 554 893-898. 555 Cuevas-Covarrubias SA, Juarez-Oropeza MA, Miranda-Zamora R & Diaz-Zagoya JC 1993 556 557 Comparative analysis of human steroid sulfatase activity in prepubertal and postpubertal males and females. Biochem Mol Biol Int 30 691-695. 558

- 559 Cuevas-Covarrubias SA, Valdes-Flores M, Orozco Orozco E, Diaz-Zagoya JC & Kofman-Alfaro
- SH 1999 Most "sporadic" cases of X-linked ichthyosis are not de novo mutations. *Acta Derm*
- 561 *Venereol* **79** 143-144.
- Davies W 2012 Does steroid sulfatase deficiency influence postpartum psychosis risk? *Trends*
- 563 *Mol Med* **18** 256-262.
- Davies W 2017 Understanding the pathophysiology of postpartum psychosis: Challenges and
- new approaches. World J Psychiatry 7 77-88.
- Davies W, Humby T, Kong W, Otter T, Burgoyne PS & Wilkinson LS 2009 Converging
- 567 pharmacological and genetic evidence indicates a role for steroid sulfatase in attention. *Biol*
- 568 *Psychiatry* **66** 360-367.
- 569 Davies W, Humby T, Trent S, Eddy JB, Ojarikre OA & Wilkinson LS 2014 Genetic and
- 570 pharmacological modulation of the steroid sulfatase axis improves response control;
- 571 comparison with drugs used in ADHD. *Neuropsychopharmacology* **39** 2622-2632.
- 572 Dias NJ & Selcer KW 2016 Steroid sulfatase in the human MG-63 preosteoblastic cell line:
- 573 Antagonistic regulation by glucocorticoids and NFkappaB. *Mol Cell Endocrinol* **420** 85-96.
- 574 Dietsche B, Kircher T & Falkenberg I 2017 Structural brain changes in schizophrenia at
- 575 different stages of the illness: A selective review of longitudinal magnetic resonance imaging
- 576 studies. *Aust N Z J Psychiatry* **51** 500-508.
- 577 Egerton A, Modinos G, Ferrera D & McGuire P 2017 Neuroimaging studies of GABA in
- schizophrenia: a systematic review with meta-analysis. *Transl Psychiatry* **7** e1147.
- Farrar D, Tuffnell D, Neill J, Scally A & Marshall K 2014 Assessment of cognitive function across
- pregnancy using CANTAB: a longitudinal study. *Brain Cogn* **84** 76-84.
- Fernandes NF, Janniger CK & Schwartz RA 2010 X-linked ichthyosis: an oculocutaneous
- genodermatosis. J Am Acad Dermatol 62 480-485.

583 Fusar-Poli P, Borgwardt S, Crescini A, Deste G, Kempton MJ, Lawrie S, Mc Guire P & Sacchetti E 2011 Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci 584 585 *Biobehav Rev* **35** 1175-1185. Gammie SC, Driessen TM, Zhao C, Saul MC & Eisinger BE 2016 Genetic and neuroendocrine 586 regulation of the postpartum brain. Front Neuroendocrinol 42 1-17. 587 Gelman PL, Flores-Ramos M, Lopez-Martinez M, Fuentes CC & Grajeda JP 2015 Hypothalamic-588 589 pituitary-adrenal axis function during perinatal depression. Neurosci Bull 31 338-350. 590 Gentile S 2005 The role of estrogen therapy in postpartum psychiatric disorders: an update. 591 CNS Spectr **10** 944-952. 592 Geyer J, Bakhaus K, Bernhardt R, Blaschka C, Dezhkam Y, Fietz D, Grosser G, Hartmann K, Hartmann MF, Neunzig J, et al. 2017 The role of sulfated steroid hormones in reproductive 593 processes. J Steroid Biochem Mol Biol 172 207-221. 594 595 Gratton AM, Ye L, Brownfoot FC, Hannan NJ, Whitehead C, Cannon P, Deo M, Fuller PJ, Tong 596 S & Kaitu'u-Lino TJ 2016 Steroid sulfatase is increased in the placentas and whole blood of women with early-onset preeclampsia. Placenta 48 72-79. 597 598 Hampson E, Phillips SD, Soares CN & Steiner M 2013 Steroid concentrations in antepartum and postpartum saliva: normative values in women and correlations with serum. Biol Sex 599 Differ **4** 7. 600 601 Harrison PJ 2015 Recent genetic findings in schizophrenia and their therapeutic relevance. J Psychopharmacol 29 85-96. 602 Hill M, Parizek A, Klak J, Hampl R, Sulcova J, Havlikova H, Lapcik O, Bicikova M, Fait T, Kancheva 603 R, et al. 2002 Neuroactive steroids, their precursors and polar conjugates during parturition 604 605 and postpartum in maternal and umbilical blood: 3.3beta-hydroxy-5-ene steroids. J Steroid Biochem Mol Biol 82 241-250. 606

607 Humby T, Cross ES, Messer L, Guerrero S & Davies W 2016 A pharmacological mouse model suggests a novel risk pathway for postpartum psychosis. Psychoneuroendocrinology 74 363-608 370. 609 610 Humby T, Fisher A, Allen C, Reynolds M, Hartman A, Giegling I, Rujescu D & Davies W 2017 A genetic variant within STS previously associated with inattention in boys with attention deficit 611 hyperactivity disorder is associated with enhanced cognition in healthy adult males. Brain 612 613 *Behav* **7** e00646. 614 Idkowiak J, Taylor AE, Subtil S, O'Neil DM, Vijzelaar R, Dias RP, Amin R, Barrett TG, Shackleton 615 CH, Kirk JM, et al. 2016 Steroid Sulfatase Deficiency and Androgen Activation Before and After 616 Puberty. J Clin Endocrinol Metab 101 2545-2553. 617 Jiang M, Klein M, Zanger UM, Mohammad MK, Cave MC, Gaikwad NW, Dias NJ, Selcer KW, Guo Y, He J, et al. 2016 Inflammatory regulation of steroid sulfatase: A novel mechanism to 618 619 control estrogen homeostasis and inflammation in chronic liver disease. *J Hepatol* **64** 44-52. 620 Jones I, Chandra PS, Dazzan P & Howard LM 2014 Bipolar disorder, affective psychosis, and 621 schizophrenia in pregnancy and the post-partum period. Lancet 384 1789-1799. 622 Jones I, Hamshere M, Nangle JM, Bennett P, Green E, Heron J, Segurado R, Lambert D, Holmans P, Corvin A, et al. 2007 Bipolar affective puerperal psychosis: genome-wide 623 significant evidence for linkage to chromosome 16. Am J Psychiatry 164 1099-1104. 624 Kent L, Emerton J, Bhadravathi V, Weisblatt E, Pasco G, Willatt LR, McMahon R & Yates JR 625 626 2008 X-linked ichthyosis (steroid sulfatase deficiency) is associated with increased risk of 627 attention deficit hyperactivity disorder, autism and social communication deficits. J Med Genet 45 519-524. 628 Kriz L, Bicikova M, Mohapl M, Hill M, Cerny I & Hampl R 2008 Steroid sulfatase and sulfuryl 629 630 transferase activities in human brain tumors. J Steroid Biochem Mol Biol 109 31-39.

631 Kuijper EA, Ket JC, Caanen MR & Lambalk CB 2013 Reproductive hormone concentrations in pregnancy and neonates: a systematic review. Reprod Biomed Online 27 33-63. 632 Kumar HB, Purushottam M, Kubendran S, Gayathri P, Mukherjee O, Murthy AR, Ghosh S, 633 634 Chandra P, Reddy YC, Benegal V, et al. 2007 Serotonergic candidate genes and puerperal psychosis: an association study. *Psychiatr Genet* **17** 253-260. 635 Kumar MM, Venkataswamy MM, Sathyanarayanan G, Thippeswamy H, Chandra PS & Mani 636 637 RS 2017 Immune system aberrations in postpartum psychosis: An immunophenotyping study 638 from a tertiary care neuropsychiatric hospital in India. J Neuroimmunol 310 8-13. Langlois S, Armstrong L, Gall K, Hulait G, Livingston J, Nelson T, Power P, Pugash D, Siciliano 639 640 D, Steinraths M, et al. 2009 Steroid sulfatase deficiency and contiguous gene deletion syndrome amongst pregnant patients with low serum unconjugated estriols. Prenat Diagn 29 641 966-974. 642 643 Lazaridis I, Charalampopoulos I, Alexaki VI, Avlonitis N, Pediaditakis I, Efstathopoulos P, 644 Calogeropoulou T, Castanas E & Gravanis A 2011 Neurosteroid dehydroepiandrosterone interacts with nerve growth factor (NGF) receptors, preventing neuronal apoptosis. PLoS Biol 645 **9** e1001051. 646 Lonstein JS, Levy F & Fleming AS 2015 Common and divergent psychobiological mechanisms 647 underlying maternal behaviors in non-human and human mammals. Horm Behav 73 156-185. 648 Lykkesfeldt G, Bennett P, Lykkesfeldt AE, Micic S, Moller S & Svenstrup B 1985 Abnormal 649 androgen and estrogen metabolism in men with steroid sulphatase deficiency and recessive 650 651 X-linked ichthyosis. Clin Endocrinol (Oxf) 23 385-393. Maayan R, Abou-Kaud M, Strous RD, Kaplan B, Fisch B, Shinnar N & Weizman A 2004a The 652 influence of parturition on the level and synthesis of sulfated and free neurosteroids in rats. 653 654 Neuropsychobiology 49 17-23.

655 Maayan R, Shaltiel G, Poyurovsky M, Ramadan E, Morad O, Nechmad A, Weizman A & Agam G 2004b Chronic lithium treatment affects rat brain and serum dehydroepiandrosterone 656 657 (DHEA) and DHEA-sulphate (DHEA-S) levels. Int J Neuropsychopharmacol 7 71-75. 658 Makieva S, Saunders PT & Norman JE 2014 Androgens in pregnancy: roles in parturition. Hum *Reprod Update* **20** 542-559. 659 Malik A, Amer AB, Salama M, Haddad B, Alrifai MT, Al Balwi M, Davies W & Eyaid W 2017 X-660 661 linked ichthyosis associated with psychosis and behavioral abnormalities: a case report. Journal of Medical Case Reports. 662 Maninger N, Wolkowitz OM, Reus VI, Epel ES & Mellon SH 2009 Neurobiological and 663 664 neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front Neuroendocrinol 30 65-91. 665 Marrs CR, Ferraro DP & Cross CL 2010 Hormones and mood across the first postpartum year. 666 667 Eur J Obstet Gynecol Reprod Biol 149 121-122. 668 Marrs CR, Ferraro DP, Cross CL & Rogers SL 2009 A potential role for adrenal androgens in postpartum psychiatric distress. Eur J Obstet Gynecol Reprod Biol 143 127-128. 669 670 Meltzer HY, Massey BW & Horiguchi M 2012 Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol 13 1572-671 1586. 672 673 Miki Y, Nakata T, Suzuki T, Darnel AD, Moriya T, Kaneko C, Hidaka K, Shiotsu Y, Kusaka H & Sasano H 2002 Systemic distribution of steroid sulfatase and estrogen sulfotransferase in 674 human adult and fetal tissues. J Clin Endocrinol Metab 87 5760-5768. 675 Milunsky J, Huang XL, Wyandt HE & Milunsky A 1999 Schizophrenia susceptibility gene locus 676

677

at Xp22.3. Clin Genet **55** 455-460.

678 Miranda-Duarte A, Valdes-Flores M, Miranda-Zamora R, Diaz-Zagoya JC, Kofman-Alfaro SH & Cuevas-Covarrubias SA 1999 Steroid sulfatase activity in leukocytes: a comparative study in 679 680 45,X; 46,Xi(Xq) and carriers of steroid sulfatase deficiency. Biochem Mol Biol Int 47 137-142. Miyakawa I, Kawano Y, Taniyama K & Mori N 1994 Steroid sulfatase activity in human 681 leukocytes. Gynecol Obstet Invest 38 191-193. 682 Mortaud S, Donsez-Darcel E, Roubertoux PL & Degrelle H 1996 Murine steroid sulfatase gene 683 684 expression in the brain during postnatal development and adulthood. Neurosci Lett 215 145-685 148. Mueller JW, Gilligan LC, Idkowiak J, Arlt W & Foster PA 2015 The Regulation of Steroid Action 686 687 by Sulfation and Desulfation. *Endocr Rev* **36** 526-563. Nakamura Y, Miki Y, Suzuki T, Nakata T, Darnel AD, Moriya T, Tazawa C, Saito H, Ishibashi T, 688 Takahashi S, et al. 2003 Steroid sulfatase and estrogen sulfotransferase in the atherosclerotic 689 690 human aorta. *Am J Pathol* **163** 1329-1339. 691 Neunzig J & Bernhardt R 2014 Dehydroepiandrosterone sulfate (DHEAS) stimulates the first 692 step in the biosynthesis of steroid hormones. *PLoS One* **9** e89727. 693 Nicolas LB & Fry JP 2007 The steroid sulfatase inhibitor COUMATE attenuates rather than enhances access of dehydroepiandrosterone sulfate to the brain in the mouse. Brain Res 1174 694 92-96. 695 696 Nieschlag E, Walk T & Schindler AE 1974 Dehydroepiandrosterone (DHA) and DHA-sulphate during pregnancy in maternal blood. *Horm Metab Res* **6** 170-171. 697 698 Olincy A & Freedman R 2012 Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the alpha7 nicotinic receptor. Handb Exp Pharmacol 211-232. 699 700 Pawluski JL, Lonstein JS & Fleming AS 2017 The Neurobiology of Postpartum Anxiety and

701

Depression. *Trends Neurosci* **40** 106-120.

- 702 Peixoto C, Carrilho CG, Barros JA, Ribeiro TT, Silva LM, Nardi AE, Cardoso A & Veras AB 2017
- 703 The effects of dehydroepiandrosterone on sexual function: a systematic review. *Climacteric*
- 704 **20** 129-137.
- 705 Peixoto C, Devicari Cheda JN, Nardi AE, Veras AB & Cardoso A 2014 The effects of
- dehydroepiandrosterone (DHEA) in the treatment of depression and depressive symptoms in
- other psychiatric and medical illnesses: a systematic review. *Curr Drug Targets* **15** 901-914.
- 708 Perumal AS & Robins E 1973 Regional and subcellular distribution of aryl-and steroid
- 709 sulfatases in brain. Brain Res 59 349-358.
- 710 Pluchino N, Drakopoulos P, Bianchi-Demicheli F, Wenger JM, Petignat P & Genazzani AR 2015
- Neurobiology of DHEA and effects on sexuality, mood and cognition. J Steroid Biochem Mol
- 712 *Biol* **145** 273-280.
- 713 Purohit A & Foster PA 2012 Steroid sulfatase inhibitors for estrogen- and androgen-
- 714 dependent cancers. *J Endocrinol* **212** 99-110.
- 715 Qaiser MZ, Dolman DEM, Begley DJ, Abbott NJ, Cazacu-Davidescu M, Corol DI & Fry JP 2017
- 716 Uptake and metabolism of sulphated steroids by the blood-brain barrier in the adult male rat.
- 717 *J Neurochem* **142** 672-685.
- 718 Quilter CR, Blott SC, Wilson AE, Bagga MR, Sargent CA, Oliver GL, Southwood OI, Gilbert CL,
- 719 Mileham A & Affara NA 2007 Porcine maternal infanticide as a model for puerperal psychosis.
- 720 Am J Med Genet B Neuropsychiatr Genet **144B** 862-868.
- Reed MJ, Purohit A, Woo LW, Newman SP & Potter BV 2005 Steroid sulfatase: molecular
- biology, regulation, and inhibition. *Endocr Rev* **26** 171-202.
- 723 Rhodes ME, Li PK, Burke AM & Johnson DA 1997 Enhanced plasma DHEAS, brain acetylcholine
- and memory mediated by steroid sulfatase inhibition. *Brain Res* **773** 28-32.

- 725 Rhodes ME, Li PK, Flood JF & Johnson DA 1996 Enhancement of hippocampal acetylcholine
- release by the neurosteroid dehydroepiandrosterone sulfate: an in vivo microdialysis study.
- 727 Brain Res **733** 284-286.
- 728 Riecher-Rossler A 2017 Estrogens, prolactin, hypothalamic-pituitary-gonadal axis, and
- schizophrenic psychoses. *Lancet Psychiatry* **4** 63-72.
- 730 Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A & Rutkowski R 2014
- 731 Dehydroepiandrosterone (DHEA): hypes and hopes. *Drugs* **74** 1195-1207.
- Salido EC, Yen PH, Barajas L & Shapiro LJ 1990 Steroid sulfatase expression in human placenta:
- immunocytochemistry and in situ hybridization study. *J Clin Endocrinol Metab* **70** 1564-1567.
- 734 Salman ED, Faye-Petersen O & Falany CN 2011 Hydroxysteroid sulfotransferase 2B1b
- expression and localization in normal human brain. *Horm Mol Biol Clin Investig* **8** 445-454.
- 736 Schury K, Koenig AM, Isele D, Hulbert AL, Krause S, Umlauft M, Kolassa S, Ziegenhain U,
- 737 Karabatsiakis A, Reister F, et al. 2017 Alterations of hair cortisol and dehydroepiandrosterone
- in mother-infant-dyads with maternal childhood maltreatment. BMC Psychiatry 17 213.
- 739 Selvaraj S, Arnone D, Cappai A & Howes O 2014 Alterations in the serotonin system in
- schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging
- 741 studies. Neurosci Biobehav Rev 45 233-245.
- 742 Sexton MB, Hamilton L, McGinnis EW, Rosenblum KL & Muzik M 2015 The roles of resilience
- and childhood trauma history: main and moderating effects on postpartum maternal mental
- health and functioning. *J Affect Disord* **174** 562-568.
- 745 Shapiro LJ, Mohandas T, Weiss R & Romeo G 1979 Non-inactivation of an x-chromosome locus
- 746 in man. *Science* **204** 1224-1226.
- 747 Sharma V & Sommerdyk C 2015 Obsessive-compulsive disorder in the postpartum period:
- 748 diagnosis, differential diagnosis and management. Womens Health (Lond) 11 543-552.

- Skalkidou A, Hellgren C, Comasco E, Sylven S & Sundstrom Poromaa I 2012 Biological aspects
- of postpartum depression. Womens Health (Lond) **8** 659-672.
- 751 Soares CN & Phillips SD 2006 Hormones in the treatment of depression. Womens Health
- 752 *(Lond)* **2** 435-445.
- Soldin OP, Guo T, Weiderpass E, Tractenberg RE, Hilakivi-Clarke L & Soldin SJ 2005 Steroid
- hormone levels in pregnancy and 1 year postpartum using isotope dilution tandem mass
- 755 spectrometry. Fertil Steril 84 701-710.
- 756 Soma KK, Rendon NM, Boonstra R, Albers HE & Demas GE 2015 DHEA effects on brain and
- 757 behavior: insights from comparative studies of aggression. J Steroid Biochem Mol Biol 145
- 758 261-272.
- 759 Speisman BB, Storch EA & Abramowitz JS 2011 Postpartum obsessive-compulsive disorder. J
- 760 Obstet Gynecol Neonatal Nurs 40 680-690.
- 761 Starka L, Duskova M & Hill M 2015 Dehydroepiandrosterone: a neuroactive steroid. J Steroid
- 762 *Biochem Mol Biol* **145** 254-260.
- Stergiakouli E, Langley K, Williams H, Walters J, Williams NM, Suren S, Giegling I, Wilkinson LS,
- Owen MJ, O'Donovan MC, et al. 2011 Steroid sulfatase is a potential modifier of cognition in
- attention deficit hyperactivity disorder. *Genes Brain Behav* **10** 334-344.
- 766 Stewart DE & Vigod S 2016 Postpartum Depression. *N Engl J Med* **375** 2177-2186.
- 767 Strous RD, Spivak B, Yoran-Hegesh R, Maayan R, Averbuch E, Kotler M, Mester R & Weizman
- 768 A 2001 Analysis of neurosteroid levels in attention deficit hyperactivity disorder. Int J
- 769 Neuropsychopharmacol 4 259-264.
- 770 Tagawa N, Hidaka Y, Takano T, Shimaoka Y, Kobayashi Y & Amino N 2004 Serum
- concentrations of dehydroepiandrosterone and dehydroepiandrosterone sulfate and their

- relation to cytokine production during and after normal pregnancy. Clin Chim Acta 340 187-
- 773 193.
- Tal R, Taylor HS, Burney RO, Mooney SB & Giudice LC 2000 Endocrinology of Pregnancy. In
- 775 Endotext. Eds LJ De Groot, G Chrousos, K Dungan, KR Feingold, A Grossman, JM Hershman, C
- Koch, M Korbonits, R McLachlan, M New, et al. South Dartmouth (MA).
- 777 Trent S, Cassano T, Bedse G, Ojarikre OA, Humby T & Davies W 2012a Altered serotonergic
- function may partially account for behavioral endophenotypes in steroid sulfatase-deficient
- mice. *Neuropsychopharmacology* **37** 1267-1274.
- 780 Trent S & Davies W 2013 Cognitive, behavioral and psychiatric phenotypes associated with
- 781 steroid sulfatase deficiency. World Journal of Translational Medicine **2** 1-12.
- Trent S, Dean R, Veit B, Cassano T, Bedse G, Ojarikre OA, Humby T & Davies W 2013 Biological
- 783 mechanisms associated with increased perseveration and hyperactivity in a genetic mouse
- model of neurodevelopmental disorder. *Psychoneuroendocrinology* **38** 1370-1380.
- 785 Trent S, Dennehy A, Richardson H, Ojarikre OA, Burgoyne PS, Humby T & Davies W 2012b
- 786 Steroid sulfatase-deficient mice exhibit endophenotypes relevant to attention deficit
- 787 hyperactivity disorder. *Psychoneuroendocrinology* **37** 221-229.
- 788 Ugele B & Regemann K 2000 Differential increase of steroid sulfatase activity in XX and XY
- 789 trophoblast cells from human term placenta with syncytia formation in vitro. Cytogenet Cell
- 790 Genet **90** 40-46.
- 791 VanderKruik R, Barreix M, Chou D, Allen T, Say L, Cohen LS & Maternal Morbidity Working G
- 792 2017 The global prevalence of postpartum psychosis: a systematic review. *BMC Psychiatry* **17**
- 793 272.
- 794 Vukadinovic Z 2014 NMDA receptor hypofunction and the thalamus in schizophrenia. *Physiol*
- 795 *Behav* **131** 156-159.

796 Wang LJ, Chan WC, Chou MC, Chou WJ, Lee MJ, Lee SY, Lin PY, Yang YH & Yen CF 2017 797 Polymorphisms of STS gene and SULT2A1 gene and neurosteroid levels in Han Chinese boys 798 with attention-deficit/hyperactivity disorder: an exploratory investigation. Sci Rep 7 45595. Yen PH, Marsh B, Allen E, Tsai SP, Ellison J, Connolly L, Neiswanger K & Shapiro LJ 1988 The 799 human X-linked steroid sulfatase gene and a Y-encoded pseudogene: evidence for an 800 inversion of the Y chromosome during primate evolution. Cell 55 1123-1135. 801 Yue XH, Tong JQ, Wang ZJ, Zhang J, Liu X, Liu XJ, Cai HY & Qi JS 2016 Steroid sulfatase inhibitor 802 DU-14 protects spatial memory and synaptic plasticity from disruption by amyloid beta 803 804 protein in male rats. Horm Behav 83 83-92.